Valuation

Four big questions about China’s first top-down FRAND ruling, answered

Dragon Wang of Sitao IP says Huawei v Conversant judgment out of Nanjing is not as damaging for licensors as it may appear

Four big questions about China’s first top-down FRAND ruling, answered
It’s not all bad news for biopharma IP monetisation during coronavirus slowdown
13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline

Bypass covid-19 drug patents demand US state attorney generals
11 Aug 2020

Bypass covid-19 drug patents demand US state attorney generals

The pandemic has puts compulsory licensing firmly on the agenda in the country that is friendliest to life sciences IP owners

Latest

View all
12 Aug 2020

The best way to value biotech for deal making and investments

Why analysts must look beyond traditional valuation methodologies to an alternative ‘real options’ framework Read more

10 Aug 2020

Report: half of failed IPOs on Shanghai tech board sidelined for IP reasons

No fewer than 17 companies have had listing plans scuppered due to a variety of IP deficiencies Read more

5 Aug 2020

Inside China's first top-down FRAND royalty decision

Exclusive analysis of the recently published full judgment of the Nanjing Intermediate People's Court in Huawei v Conversant Read more

31 Jul 2020

Top patent owners continue to outperform the markets, according to new analysis

Publicly-quoted companies in the IAM/ktMINE US Patent 100 enjoyed a strong June compared to their peers Read more

News

View all
20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

7 Jul 2020

A patent's journey from IAM Market to Facebook v BlackBerry

Analysis shows that assets listed on the platform sell at a higher rate than average, while they are also litigated more often Read more

26 May 2020

WHO covid-19 IP pool launches this week without strong pharma support

Open and global sharing of patents, data and know-how is seen as a step too far by many life sciences innovators Read more

21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

Analysis

View all
30 Jul 2020

China passes a major threshold in life sciences IP reform

Move to implement patent linkage is the clearest sign yet that the country is embracing pharma and biotech innovation Read more

29 Jul 2020

Clarivate's acquisition of CPA Global raises plenty of questions

Deal creates an IP behomoth and continues the trend towards service provider consolidation - but the new company's clients will need reassurances Read more

24 Jul 2020

Patent risk profile front and centre in run up to Ant Group’s IPO

The company’s filings have exploded since the second half of 2019 and, while it is difficult to discern the quality of the assets, the portfolio is in capable hands Read more

23 Jul 2020

How to price the IP rights underpinning disruptive biotech innovation

Analysts must look beyond traditional valuation methodologies to an alternative real options framework if they are to get the most bang for their buck Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

1 Oct 2017

A round-up of IP-related quotes, observations and opinions from the recent past …

A round-up of IP-related quotes, observations and opinions from the recent past …

Read more

30 Sep 2016

McRO gives hope to US patent owners, but Section 101 uncertainty remains

After two years of uncertainty and no little gloom, a recent Federal Circuit decision may just herald the long-awaited swing-back in the pendulum that software patent owners in the United States have been waiting for. Some, though, still believe that Congress must bite the bullet and take a look at Section 101 Read more

1 Aug 2016

Brexit leaves the UPC in limbo – and that’s no bad thing

The UK vote to leave the European Union may have surprised and disappointed many in the IP community, but a rush to bypass the decision and implement the unitary patent package would be a mistake

Read more

Find an expert

Justin Blok
Managing Director
Houston, United States
Whitley Penn, LLP